H.C. Wainwright reiterated a Buy rating on Acadia Pharmaceuticals (NASDAQ: ACAD) with a price target of $50. Comments follow the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid March 30, 2016 6:49 AM Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID March 29, 2016 7:05 AM Leerink Affirms ACADIA Pharma (ACAD) at 'Outperform'; Pimavanserin Briefing Docs More Crticial than ExpectedMarch 28, 2016 7:25 AM Acadia Pharma (ACAD) Shares Active Ahead of NUPLAZID FDA PanelMarch 28, 2016 7:03 AM